Trans et al. reported that the application of adoptive cell therapy (ACT) using neoantigen ERBB2 (HER2) interaction protein-specific CD4+ tumor-infiltrating lymphocytes (TILs) achieved tumor regression in a patient with metastatic cholangiocarcinoma [44]. This evidence concerns the gene ERBB2 and neoplasm.